Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.
InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today!
Carvana
What happened? On Monday, UBS initiated coverage on Carvana Co (NYSE:CVNA) at Buy with a $450 price target.
*TLDR: Carvana targets massive growth from tiny base. UBS bullish despite uncertain consumer adoption.
What’s the full story? Carvana runs a slick online used-car operation that captures just 1.5% of the market today—a rounding error in America’s vast automotive bazaar. Yet UBS reckons this digital dealer marches toward 4% share by decade’s end, perhaps 8% within ten years, chasing their audacious 3-million vehicle target. The team’s 2026/27 EBITDA projections sit 5% above Street consensus, projecting 25% annual growth through the 2020s—numbers that justify the premium valuation if you squint hard enough.
The bull case writes itself: online penetration sits at a laughable 2% of used vehicle sales while Carvana’s platform apparently delivers both superior experience and pricing (UBS Evidence Lab confirms this, naturally). Their gross profit per unit runs double the industry average—a feat that impresses even skeptics.
The team expects further GPU expansion as inspection centers mature and ADESA auction sites integrate, creating a virtuous cycle where better sourcing feeds retail volume, which improves sourcing, and so forth.
Whether consumers actually want their cars delivered like Amazon packages remains the trillion-dollar question.
Circle Internet Group
What happened? On Tuesday, Wolfe Research initiated coverage on Circle Internet Group Inc (NYSE:CRCL) at Underperform with a $60 price target.
*TLDR: Circle’s stablecoin empire prints billions from interest. Competition and rate cuts threaten everything.
What’s the full story? Circle sits fat and happy as the world’s second-largest stablecoin dealer, riding Tether’s coattails while pushing its regulatory-friendly schtick to traditional finance dinosaurs. The company prints money—literally—with USDC’s $75 billion market cap doubling year-over-year and EURC adding pocket change at $315 million. The racket generates $2.75 billion in 2025 revenues, with 96% coming from the interest income gravy train and margins that would make a loan shark blush: over 50% adjusted EBITDA on revenue less distribution costs.
But the party’s hitting speed bumps. Distribution partners are bleeding Circle’s margins dry, while looming rate cuts threaten to vaporize their interest income goldmine. Competition circles like vultures—Tether’s launching USAT, banks are tokenizing deposits, and players like Paxos and Ripple smell blood in the water. Meanwhile, emerging markets aren’t thrilled about dollar colonization through stablecoins, and central banks plot their own digital currency revenge.
Circle’s betting its future on becoming the full-stack infrastructure overlord of the "new global internet economy"—whatever that means. The firm rolls out Arc blockchain and Circle Payments Network for cross-border transfers, but adoption remains embryonic. Wolfe notes Circle’s prioritizing user growth over monetization, gambling these platform extensions become tomorrow’s revenue lifeline when today’s interest income party inevitably ends.
Aardvark Therapeutics
What happened? On Wednesday, Raymond James initiated coverage on Aardvark Therapeutics Inc (NASDAQ:AARD) at Strong buy with a $47 price target.
*TLDR: Soleno’s Prader-Willi drug disappoints despite revenue. Aardvark offers better efficacy, massive discount.
What’s the full story? In the grand theater of biotech speculation, where desperate parents meet Wall Street’s finest vultures, Prader-Willi syndrome presents that rarest of creatures: actual unmet medical need. These poor souls can’t stop eating—literally—and Soleno’s Vykat XR, despite hauling in $66 million last quarter as the first approved therapy, apparently works about as well as telling a starving man to practice mindfulness. Raymond James’s KOL chorus sings unanimous disappointment.
Enter Aardvark’s ARD-101, targeting gut receptors to trick the body into feeling full—a molecular sleight of hand that Phase 2 data suggests actually works. The firm notes the delicious valuation arbitrage: Aardvark trades at sub-$100 million enterprise value while Soleno commands $2 billion for inferior results. With Phase 3 data coming third quarter 2026, this setup offers what Twain might call "a sure thing wrapped in uncertainty’s clothing."
The kicker? Aardvark’s pursuing obesity indications—because why cure rare diseases when you can chase the American dream of treating everyone who supersized their existence. Raymond James sees unmodeled upside, which in biotech parlance means "lottery tickets are still cheap."
O-Reilly Auto
What happened? On Thursday (Wednesday after-hours), Baird launched new coverage on O’Reilly Automotive Inc (NASDAQ:ORLY) at Outperform with a $115 price target.
*TLDR: O’Reilly prints money despite retail apocalypse. Overvalued but keeps compounding regardless.
What’s the full story? In the grand casino of American retail, where tariffs threaten to vaporize margins faster than a Tesla battery in flames, O’Reilly Automotive stands as that peculiar beast: a boring company printing money. The analysts at Baird genuflect before ORLY’s "value creation machine"—Wall Street speak for "they buy competitors and jack up prices on spark plugs." Management runs the same playbook year after year, which in this market passes for genius.
The stock trades at 30 times forward earnings versus its three-year average of 26 times, because apparently nothing says "bargain" quite like paying a 15% premium for the privilege of owning an auto parts retailer. But here’s the beautiful absurdity: while Amazon incinerates traditional retail and Chinese tariffs loom like Twain’s comet, ORLY keeps compounding. Baird sees margin inflection ahead—translation: they’ll squeeze more juice from the same lemons. The analysts remain "highly confident," which in this business means they’re either prophets or the last fools at the poker table.
Parsons Corp
What happened? On Friday, Raymond James double downgraded Parsons Corp (NYSE:PSN) to Market Perform and removed its price target.
*TLDR: Parsons lost FAA contract to Peraton. Overvalued stock faces massive valuation correction.
What’s the full story? In the grand tradition of Wall Street’s finest miscalculations, Parsons just discovered that counting chickens before they hatch remains hazardous to share prices. The FAA handed its $12.5 billion air traffic control modernization contract—charmingly acronymed BNATCS—to Peraton, not Parsons, sending Raymond James scrambling to downgrade PSN from Strong Buy to Market Perform, which translates to "oops, never mind."
The firm notes PSN’s stock had climbed to nosebleed valuations, trading at a 35% premium to peers on the delusion this contract was theirs. That premium now faces what Twain might call "a great awakening to disappointment." Raymond James expects it to evaporate faster than confidence at a bank run, perhaps halving as investors realize their "sure thing" just became Peraton’s payday. The psyche of the stock is "dented," they observe—Wall Street’s euphemism for "shareholders are about to discover gravity." With catalysts now "ambiguous," the analysts essentially admit they’re as lost as everyone else who bet on this bureaucratic beauty contest.








